Article
F18, a novel small-molecule nonnucleoside reverse transcriptase inhibitor, inhibits HIV-1 replication using distinct binding motifs as demonstrated by resistance selection and docking analysis.
Antimicrobial agents and chemotherapy - 1 Jan 2012
Lu Xiaofan, Liu Li, Zhang Xu, Lau Terrence Chi Kong, Tsui Stephen Kwok Wing, Kang Yuanxi, Zheng Purong, Zheng Bojian, Liu Gang, Chen Zhiwei
Abstract excerpt
Nonnucleoside reverse transcriptase inhibitors (NNRTIs) are one of the key components of antiretroviral therapy drug regimen against human immunodeficiency virus type 1 (HIV-1) replication. We previously described a newly synthesized small molecule, 10-chloromethyl-11-demethyl-12-oxo-calanolide A (F18), a (+)-calanolide A analog, as a novel anti-HIV-1 NNRTI (H. Xue et al., J. Med. Chem. 53:1397-1401, 2010). Here,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.